FR2444466A1 - PROCESS FOR THE MANUFACTURE OF VACCINES AGAINST THE EARLY SUMMER MENINGOENCEPHALITY VIRUS (FSME VIRUS) AND VACCINES OBTAINED THEREBY - Google Patents

PROCESS FOR THE MANUFACTURE OF VACCINES AGAINST THE EARLY SUMMER MENINGOENCEPHALITY VIRUS (FSME VIRUS) AND VACCINES OBTAINED THEREBY

Info

Publication number
FR2444466A1
FR2444466A1 FR7931278A FR7931278A FR2444466A1 FR 2444466 A1 FR2444466 A1 FR 2444466A1 FR 7931278 A FR7931278 A FR 7931278A FR 7931278 A FR7931278 A FR 7931278A FR 2444466 A1 FR2444466 A1 FR 2444466A1
Authority
FR
France
Prior art keywords
virus
vaccines
fsme
early summer
meningoencephality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7931278A
Other languages
French (fr)
Other versions
FR2444466B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG, Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG
Publication of FR2444466A1 publication Critical patent/FR2444466A1/en
Application granted granted Critical
Publication of FR2444466B1 publication Critical patent/FR2444466B1/fr
Granted legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B28—WORKING CEMENT, CLAY, OR STONE
    • B28D—WORKING STONE OR STONE-LIKE MATERIALS
    • B28D1/00—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor
    • B28D1/02—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor by sawing
    • B28D1/06—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor by sawing with reciprocating saw-blades
    • B28D1/068—Components, e.g. guiding means, vibrations damping means, frames, driving means, suspension
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mining & Mineral Resources (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un procédé de fabrication de vaccins contre le virus de la méningoencéphalite du début de l'été. Pour cela, on fait une culture du virus dit virus FSME dans des cultures de tissu ou des suspensions de cellules d'embryons de poulet, puis on sépare les cellules et les fractions de cellules par centrifugation, on active le virus, on réalise une concentration et une épuration, la suspension ainsi épurée étant préparée pour faire des vaccins. Pour obtenir des vaccins ne présentant pas de risque de contre-réaction, la suspension contenant le virus est soumise à un traitement d'ultra-centrifugation continu par gradients de densité et l'on collecte les fractions de la teneur du gradient qui présentent à 260 nm une extinction accrue de l'ordre de 200 S. Les vaccins obtenus suivant l'invention sont beaucoup mieux supportés par les sujets.The present invention relates to a method of manufacturing vaccines against early summer meningoencephalitis virus. For this, we culture the virus called FSME virus in tissue cultures or suspensions of chicken embryo cells, then we separate the cells and cell fractions by centrifugation, we activate the virus, we perform a concentration and scrubbing, the suspension thus purified being prepared for making vaccines. To obtain vaccines that do not present any risk of negative reaction, the suspension containing the virus is subjected to a continuous ultra-centrifugation treatment by density gradients and the fractions of the gradient content which exhibit at 260 are collected. nm an increased extinction of the order of 200 S. The vaccines obtained according to the invention are much better tolerated by the subjects.

FR7931278A 1978-12-22 1979-12-20 PROCESS FOR THE MANUFACTURE OF VACCINES AGAINST THE EARLY SUMMER MENINGOENCEPHALITY VIRUS (FSME VIRUS) AND VACCINES OBTAINED THEREBY Granted FR2444466A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT922078A AT358167B (en) 1978-12-22 1978-12-22 METHOD FOR PRODUCING EARLY SUMMER MENINGOENZEPHALITIS VIRUS (FSME VIRUS) VACCINES

Publications (2)

Publication Number Publication Date
FR2444466A1 true FR2444466A1 (en) 1980-07-18
FR2444466B1 FR2444466B1 (en) 1983-07-08

Family

ID=3612255

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7931278A Granted FR2444466A1 (en) 1978-12-22 1979-12-20 PROCESS FOR THE MANUFACTURE OF VACCINES AGAINST THE EARLY SUMMER MENINGOENCEPHALITY VIRUS (FSME VIRUS) AND VACCINES OBTAINED THEREBY

Country Status (11)

Country Link
AT (1) AT358167B (en)
BE (1) BE880732A (en)
CH (1) CH644271A5 (en)
CS (1) CS223975B2 (en)
DE (1) DE2950004C2 (en)
FR (1) FR2444466A1 (en)
GB (1) GB2038179B (en)
IT (1) IT1126676B (en)
SE (1) SE447789B (en)
SU (2) SU1003738A3 (en)
YU (1) YU42204B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106837A2 (en) * 1982-10-05 1984-04-25 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Use of peptides
EP0203909A1 (en) * 1985-04-26 1986-12-03 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Early-summer meningo-encephalitis virus (FSME-virus) vaccine, and method of producing the same
WO1991009935A1 (en) * 1989-12-22 1991-07-11 Immuno Aktiengesellschaft Matrix with adherently bound cells and process for producing viruses/virus antigens
WO1991009937A1 (en) * 1990-01-04 1991-07-11 Immuno Aktiengesellschaft Biomass for the production of viruses/virus antigens
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305405B1 (en) * 1998-02-18 2001-05-04 Augusto Cappelli CUTTING FRAME FOR THE SEGMENT OF STONE, ROCK, GRANITE, MARBLE, OR SIMILAR BLOCKS.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1152626A (en) * 1967-07-07 1969-05-21 Merck & Co Inc Rubella Vaccine
GB1453035A (en) * 1972-12-21 1976-10-20 Secr Defence Virus vaccine production

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106837A2 (en) * 1982-10-05 1984-04-25 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Use of peptides
EP0106837A3 (en) * 1982-10-05 1986-08-27 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Peptides and peptide-containing compounds
EP0203909A1 (en) * 1985-04-26 1986-12-03 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Early-summer meningo-encephalitis virus (FSME-virus) vaccine, and method of producing the same
WO1991009935A1 (en) * 1989-12-22 1991-07-11 Immuno Aktiengesellschaft Matrix with adherently bound cells and process for producing viruses/virus antigens
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
WO1991009937A1 (en) * 1990-01-04 1991-07-11 Immuno Aktiengesellschaft Biomass for the production of viruses/virus antigens
US5550051A (en) * 1990-01-04 1996-08-27 Immuno Aktiengesellschaft Avian embryo cell aggregate biomass for producing virus/virus antigen and method for producing virus/virus antigen

Also Published As

Publication number Publication date
IT7928341A0 (en) 1979-12-21
AT358167B (en) 1980-08-25
GB2038179B (en) 1983-02-16
SE447789B (en) 1986-12-15
SU1003738A3 (en) 1983-03-07
SU1318149A3 (en) 1987-06-15
YU311779A (en) 1983-10-31
SE7910054L (en) 1980-06-23
DE2950004A1 (en) 1980-07-03
IT1126676B (en) 1986-05-21
CH644271A5 (en) 1984-07-31
FR2444466B1 (en) 1983-07-08
DE2950004C2 (en) 1991-04-18
YU42204B (en) 1988-06-30
ATA922078A (en) 1980-01-15
GB2038179A (en) 1980-07-23
BE880732A (en) 1980-04-16
CS223975B2 (en) 1983-11-25

Similar Documents

Publication Publication Date Title
Aula et al. 'Salla disease': A new lysosomal storage disorder
Dubois et al. NZB/NZW mice as a model of systemic lupus erythematosus
O'Brien et al. The α-glycerophosphate cycle in Drosophila melanogaster. I. Biochemical and developmental aspects
Wieme et al. Origin of the lactate dehydrogenase isoenzyme pattern found in the serum of patients having primary muscular dystrophy
Beard Review Purified Animal Viruses
Crawford A study of the Rous sarcoma virus by density gradient centrifugation
RU2007135220A (en) METHOD FOR TREATING RETINOPATHY IN MATTERING AND RELATIVE RETINOPATHIC DISEASES
FR2444466A1 (en) PROCESS FOR THE MANUFACTURE OF VACCINES AGAINST THE EARLY SUMMER MENINGOENCEPHALITY VIRUS (FSME VIRUS) AND VACCINES OBTAINED THEREBY
WO2020021535A1 (en) Mitochondrial augmentation therapy of ocular diseases
Gremigni et al. Cytophotometric evidence for cell ‘transdifferentiation’in planarian regeneration
CN106244521A (en) A kind of human amnion membrane, isolated culture method and purposes
Duan et al. Sequential intrastriatal grafting of allogeneic embryonic dopamine-rich neuronal tissue in adult rats: will the second graft be rejected?
Takahashi A virus inactivator from yeast
Flint et al. Bronchoalveolar mast cells in sarcoidosis: increased numbers and accentuation of mediator release.
Tolani et al. Differential metabolism of various brain regions. Biochemical heterogeneity of mitochondria
Takahashi The role of an anomalous noninfectious protein in virus synthesis
Palva et al. The origin of perilymph albumin
CN114517177A (en) Composition for enhancing mesenchymal stem cell efficiency and application thereof
CN112972493A (en) Preparation method and application of anti-aging agent
Band Biotin, a growth requirement for four soil amoebae
CN106011067A (en) Esophageal cancer cell line and application thereof
Robin et al. Passage of Marburg virus in guinea pigs
Narayan Role of macrophages in the immunopathogenesis of visna-maedi of sheep
Torvik et al. Myopathy with tremor and dementia: A metabolic disorder?: Case report with postmortem study
Engle Jr et al. Separation of human hemoglobins by starch-gel zone electrophoresis